Acalabrutinib (ACP-196) is a highly selective, Bruton's tyrosine kinase (BTK) inhibitor developed to minimize off-target activity with minimal effects on TEC, EGFR, or ITK signaling.1

As of December 2018, acalabrutinib has been administered to over 3,500 participants in clinical studies, including subjects with hematologic malignancies and solid tumors.2

Please visit to learn more about the ongoing phase 1, 2 and 3 programs.

1 Covey T, et al. Presentation at the 2015 annual AACR meeting. Abstract 2596.
2 Byrd JC, et al. N Engl J Med. 2016;374(4):323-332.